Trial reportCell2024
Selection of epigenetically privileged HIV-1 proviruses during treatment with panobinostat and interferon-α2a.
Open access · hybridAbstract readRandomized Controlled Trial
In one paragraph
Trial report in Cell, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
8.8field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 30 citations in OpenAlex.
- A Leap Forward in Vaccination - the Epigenetic Silencing of HIV by cVacc.Current HIV/AIDS reports · 2026Review
- Article
- Antigen Stimulation Reactivates HIV-1 Proviruses Despite Integration in Repressive Chromatin.bioRxiv : the preprint server for biology · 2026Article
- Review
- Tenofovir, Interferon Pathways, and Mucosal Immunity: Implications for People Living With HIV.American journal of reproductive immunology (New York, N.Y. : 1989) · 2026Review
- TGF-β mediates epigenetic control of innate antiviral responses and SIV reservoir size.Nature immunology · 2026Article
- Persistent viral control status is associated with enhanced innate immune responses in people with HIV-1.iScience · 2026Article
- Virtual Screening of FDA-Approved Compounds: Exploring New Alternatives for HIV Treatment.ACS omega · 2026Article
- Transcription of HIV-1 is heterogenous among authentic latent CD4+ T cell clones.The Journal of experimental medicine · 2026Article
- HIV-1 Integration Site Determines the Transcriptional Fate and Persistence of Integrated Proviruses.bioRxiv : the preprint server for biology · 2026Article
- High-Efficiency Genomic Mapping of Chromatin-Associated Targets with CUT&RUN.Methods in molecular biology (Clifton, N.J.) · 2026Article
- Epigenetic mechanisms of HIV and opioid-induced neuropathology: Potential therapies and interventions.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Review
- Factors associated with resistance of HIV-1 reservoir viruses to neutralization by autologous IgG antibodies.The Journal of clinical investigation · 2025Article
- Epigenetic drugs against human DNA viruses and retroviruses.Antiviral research · 2025Review
- Applications and limitations of the passenger hypothesis for HIV reservoir persistence and cure.Journal of virology · 2025Review
- Immune-mediated strategies to solving the HIV reservoir problem.Nature reviews. Immunology · 2025Review
- Histone hyperacetylation disrupts spermatogonial stem cells homeostasis and impairs spermiogenesis.Stem cell research & therapy · 2025Article
- PRMT3 reverses HIV-1 latency by increasing chromatin accessibility to form a TEAD4-P-TEFb-containing transcriptional hub.Nature communications · 2025Article
- Latency Reversing Agents and the Road to an HIV CurePathogens (Basel, Switzerland) · 2025Review
- Tannic acid reactivates HIV-1 latency by mediating CBX4 degradation.Journal of virology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 5 institutions in 1 country.
Marie Armani-TourretRagon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
Ce GaoRagon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
Ciputra Adijaya HartanaRagon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA; Division of Infectious Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
WeiWei SunRagon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
Leah CarrereRagon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA; Division of Infectious Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Liliana VelaRagon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
Alexander HochrothRagon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
Maxime BellefroidRagon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
Amy SbrollaDivision of Infectious Diseases, Massachusetts General Hospital, Boston, MA 02114, USA.
Katrina SheaDivision of Infectious Diseases, Massachusetts General Hospital, Boston, MA 02114, USA.
Theresa FlynnDivision of Infectious Diseases, Massachusetts General Hospital, Boston, MA 02114, USA.
Isabelle RosetoRagon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA; Division of Infectious Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Yelizaveta RassadkinaRagon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
Carole LeeDepartment of Microbiology, University of Pennsylvania, Philadelphia, PA 19104, USA.
Francoise GiguelDivision of Infectious Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Rajeev MalhotraDivision of Cardiology, Massachusetts General Hospital, Boston, MA 02114, USA.
Frederic D BushmanDepartment of Microbiology, University of Pennsylvania, Philadelphia, PA 19104, USA.
Rajesh T GandhiDivision of Infectious Diseases, Massachusetts General Hospital, Boston, MA 02114, USA.
Xu G YuRagon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA; Division of Infectious Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Daniel R KuritzkesDivision of Infectious Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Mathias LichterfeldRagon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA; Division of Infectious Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA. Electronic address: mlichterfeld@mgh.harvard.edu.
Ragon Institute of MGH, MIT and Harvard · USMassachusetts General Hospital · USBrigham and Women's Hospital · USHarvard University · USUniversity of Pennsylvania · US
Funding
Virus & Reservoirs CoreP30AI045008 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI Ronald G Collman · 1999 to 2026
$78.6MPediatric Adolescent Virus Elimination (PAVE) Martin Delaney CollaboratoryUM1AI164566 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Ann M Chahroudi, Deborah Persaud · 2021 to 2026
$35.5MBEAT-HIV: Delaney Collaboratory to Cure HIV-1 Infection by Combination ImmunotherapyUM1AI164570 · NIAID · WISTAR INSTITUTE · PI Luis J Montaner, James L. Riley · 2021 to 2026
$34.7MDelaney AIDS Research Enterprise to Cure HIVUM1AI164560 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI STEVEN Grant DEEKS, Sharon Ruth Lewin · 2021 to 2026
$32.0MERASE HIV: Enterprise for Research and Advancements to Stop and Eradicate HIVUM1AI164562 · NIAID · EMORY UNIVERSITY · PI Deanna A Kulpa, Mirko Paiardini · 2021 to 2026
$30.0MModeling HIV CAR-T cell trafficking and persistence in Non-Human PrimatesU19AI149680 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI RILEY, JAMES L. · 2020 to 2024
$13.2MA Pilot Clinical Trial for HIV-1 EradicationU01AI117841 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI KURITZKES, DANIEL R., LICHTERFELD, MATHIAS · 2015 to 2020
$10.7MA clinical trial to evaluate the impact of broadly neutralizing antibody VRC01 on HIV viral reservoir and maintenance of suppression in a cohort of early-treated children in BotswanaU01AI135940 · NIAID · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI KURITZKES, DANIEL R., LICHTERFELD, MATHIAS · 2018 to 2024
$10.4MGene Therapy for SCID-X1 with Low Dose Busulfan and a SIN-lentiviral VectorU01AI125051 · NIAID · BOSTON CHILDREN'S HOSPITAL · PI DAVID A WILLIAMS · 2016 to 2026
$9.7MA Phase I Clinical Trial Testing Feasibility of Hematopoietic Stem Cell Gene Therapy Using Platelet Factor VIII to Safely Improve Hemostasis for Severe Hemophilia A with Inhibitory AntibodiesR01HL142791 · NHLBI · MEDICAL COLLEGE OF WISCONSIN · PI EAPEN, MARY, WILCOX, DAVID ALLEN · 2019 to 2023
$8.2MProject 3: Defining adaptive immune interactions that shape Clostridioides difficile infectionU19AI174998 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI DREW WEISSMAN · 2023 to 2026
$7.6MElite controllers as a model for a cure of HIV-1 infectionR37AI155171 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI Xu Yu · 2020 to 2026
$5.2MNCI NIH HHS R01 CA241762NHLBI NIH HHS R01 HL134539NHLBI NIH HHS R01 HL142791NHLBI NIH HHS R01 HL160748NIAID NIH HHS K24 AI155233NIAID NIH HHS P30 AI045008NIAID NIH HHS R01 AI078799NIAID NIH HHS R01 AI130005NIAID NIH HHS R01 AI152979NIAID NIH HHS R01 AI176579NIAID NIH HHS R01 AI184094NIAID NIH HHS R21 AI116228NIAID NIH HHS R33 AI116228NIAID NIH HHS R37 AI155171NIAID NIH HHS U01 AI117841NIAID NIH HHS U01 AI125051NIAID NIH HHS U01 AI135940NIAID NIH HHS U19 AI149680NIAID NIH HHS U19 AI174998NIAID NIH HHS UM1 AI164560NIAID NIH HHS UM1 AI164562NIAID NIH HHS UM1 AI164566NIAID NIH HHS UM1 AI164570NIDA NIH HHS R33 DA047034NIDA NIH HHS R61 DA047034NIDDK NIH HHS R01 DK120387
Abstract
CD4
Indexed as
Histone Deacetylase InhibitorsHIV-1HIV InfectionsInterferon-alphaPanobinostatProvirusesHumansPolyethylene GlycolsRecombinant ProteinsVirus LatencyHistone Deacetylase InhibitorsInterferon-alphaPanobinostatpeginterferon alfa-2aPolyethylene GlycolsRecombinant Proteinsepigeneticshistone acetylationHIV-1HIV-1 cureinnate immunityintegration sitesinterferonpanobinostatshock and killviral reservoir
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.